Compugen Ltd. (NASDAQ:CGEN) Stock Has Average Target Price of $5.00 According to Analysts

Compugen Ltd. (NASDAQ:CGEN) has been assigned an average rating of “Buy” from the five analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $5.00.

CGEN has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Compugen in a report on Monday, October 12th. Weiss Ratings raised Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th.

Compugen Stock Performance

NASDAQ CGEN opened at $1.94 on Friday. Compugen has a one year low of $1.43 and a one year high of $3.23. The company has a 50-day simple moving average of $2.37 and a 200-day simple moving average of $2.42. The firm has a market capitalization of $183.43 million, a PE ratio of 5.11 and a beta of 2.78.

Compugen (NASDAQ:CGEN) last issued its earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Compugen had a net margin of 47.56% and a return on equity of 42.57%. The firm had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $1.28 million. During the same quarter last year, the company posted ($0.08) earnings per share. Equities analysts forecast that Compugen will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its position in Compugen by 12.1% in the first quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock worth $3,478,000 after buying an additional 176,088 shares during the period. WINTON GROUP Ltd lifted its stake in Compugen by 26.0% in the second quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company’s stock valued at $422,000 after buying an additional 40,614 shares during the last quarter. Platform Technology Partners lifted its stake in Compugen by 10.0% in the first quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 5,000 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Compugen during the second quarter valued at $110,000. Finally, Glenmede Trust Co. NA boosted its holdings in shares of Compugen by 187.5% during the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 22,500 shares during the period. 12.22% of the stock is currently owned by institutional investors.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines.

Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.